{"id":"https://openalex.org/W2335974686","doi":"https://doi.org/10.1177/095632029300400104","title":"Synthesis and anti-HIV Activity of a Series of 2-Indolinones and Related Analogues","display_name":"Synthesis and anti-HIV Activity of a Series of 2-Indolinones and Related Analogues","publication_year":1993,"publication_date":"1993-02-01","ids":{"openalex":"https://openalex.org/W2335974686","doi":"https://doi.org/10.1177/095632029300400104","mag":"2335974686"},"language":"en","primary_location":{"id":"doi:10.1177/095632029300400104","doi":"https://doi.org/10.1177/095632029300400104","is_oa":false,"landing_page_url":"https://doi.org/10.1177/095632029300400104","pdf_url":null,"source":{"id":"https://openalex.org/S201936961","display_name":"Antiviral chemistry & chemotherapy","issn_l":"0956-3202","issn":["0956-3202","2040-2066"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Chemistry and Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073847679","display_name":"Joanne M. Smallheer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. M. Smallheer","raw_affiliation_strings":["The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056173398","display_name":"Michael J. Otto","orcid":"https://orcid.org/0000-0002-2222-4115","observed_orcids":["https://orcid.org/0000-0002-2222-4115"]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. J. Otto","raw_affiliation_strings":["The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009927438","display_name":"Carol Amaral-Ly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. A. Amaral-Ly","raw_affiliation_strings":["The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108767178","display_name":"Richard A. Earl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. A. Earl","raw_affiliation_strings":["The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. J. Myers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. J. Myers","raw_affiliation_strings":["The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042575126","display_name":"P. Pennev","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Pennev","raw_affiliation_strings":["The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA","institution_ids":["https://openalex.org/I1316910977"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004036928","display_name":"David C. Montefiori","orcid":"https://orcid.org/0000-0003-0856-6319","observed_orcids":["https://orcid.org/0000-0003-0856-6319"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. C. Montefiori","raw_affiliation_strings":["Vanderbilt University School of Medicine, Department of Pathology, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University School of Medicine, Department of Pathology, Nashville, TN, USA","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039230580","display_name":"Mark A. Wuonola","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316910977","display_name":"DuPont (United States)","ror":"https://ror.org/03g3m1w62","country_code":"US","type":"company","lineage":["https://openalex.org/I1316910977"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. A. Wuonola","raw_affiliation_strings":["The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Du Pont Merck Pharmaceutical Company, Wilmington DE 19880, USA","institution_ids":["https://openalex.org/I1316910977"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":1500,"currency":"USD","value_usd":1500},"apc_paid":null,"fwci":2.9743,"has_fulltext":false,"cited_by_count":20,"citation_normalized_percentile":{"value":0.91630847,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":null,"biblio":{"volume":"4","issue":"1","first_page":"27","last_page":"39"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.8978999853134155,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.8978999853134155,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Synthesis and biological activity","score":0.04960000142455101,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.011300000362098217,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/2-indolinones","display_name":"2-indolinones","score":0.9990000128746033},{"id":"https://openalex.org/keywords/anti-hiv-activity","display_name":"anti-HIV activity","score":0.8679999709129333},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.8849999904632568},{"id":"https://openalex.org/keywords/antiviral-agents","display_name":"antiviral agents","score":0.6600000262260437}],"concepts":[{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.6835408210754395},{"id":"https://openalex.org/C40479148","wikidata":"https://www.wikidata.org/wiki/Q844460","display_name":"Syncytium","level":3,"score":0.6236522197723389},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.6062933802604675},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.5674076676368713},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.5526161193847656},{"id":"https://openalex.org/C114373084","wikidata":"https://www.wikidata.org/wiki/Q273499","display_name":"Chemical synthesis","level":3,"score":0.5451289415359497},{"id":"https://openalex.org/C116073593","wikidata":"https://www.wikidata.org/wiki/Q864491","display_name":"Biological activity","level":3,"score":0.4951390326023102},{"id":"https://openalex.org/C193042331","wikidata":"https://www.wikidata.org/wiki/Q1772003","display_name":"Structure\u2013activity relationship","level":3,"score":0.46242111921310425},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4097985029220581},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.38052400946617126},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.3465549349784851},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.2526801824569702}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1177/095632029300400104","doi":"https://doi.org/10.1177/095632029300400104","is_oa":false,"landing_page_url":"https://doi.org/10.1177/095632029300400104","pdf_url":null,"source":{"id":"https://openalex.org/S201936961","display_name":"Antiviral chemistry & chemotherapy","issn_l":"0956-3202","issn":["0956-3202","2040-2066"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Chemistry and Chemotherapy","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.6240000128746033,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8199999928474426,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W1555324307","https://openalex.org/W1933773138","https://openalex.org/W1960795383","https://openalex.org/W1966952510","https://openalex.org/W1981309073","https://openalex.org/W1985309935","https://openalex.org/W2005394493","https://openalex.org/W2015326137","https://openalex.org/W2018779528","https://openalex.org/W2022870006","https://openalex.org/W2036282594","https://openalex.org/W2039795021","https://openalex.org/W2043388188","https://openalex.org/W2045426562","https://openalex.org/W2050786167","https://openalex.org/W2055688067","https://openalex.org/W2065114401","https://openalex.org/W2080786231","https://openalex.org/W2086462809","https://openalex.org/W2114742412","https://openalex.org/W2128295732","https://openalex.org/W2143811153","https://openalex.org/W2247635015","https://openalex.org/W2302123358","https://openalex.org/W2316272470","https://openalex.org/W2316449484","https://openalex.org/W2333399282","https://openalex.org/W2334783452","https://openalex.org/W2505407646","https://openalex.org/W4256221661"],"related_works":["https://openalex.org/W6949266209","https://openalex.org/W2409733252","https://openalex.org/W2511334346","https://openalex.org/W2950172820","https://openalex.org/W2315898789","https://openalex.org/W2037733475","https://openalex.org/W4242450006","https://openalex.org/W2109187112","https://openalex.org/W2216057096","https://openalex.org/W2064849054"],"abstract_inverted_index":{"A":[0],"novel":[1,93],"series":[2],"of":[3,34,40,59,68,95],"2-indolinones":[4],"with":[5,65],"in":[6,61],"vitro":[7],"anti-HIV":[8,96],"(human":[9],"immunodeficiency":[10],"virus)":[11],"activity":[12],"is":[13],"described.":[14],"Two":[15],"structurally":[16],"related":[17],"compounds,":[18],"1,":[19],"3,3-(4-":[20],"N-methyl-1,2,5,6-tetrahydropyridylmethyl)-1-":[21],"phenyl-2-indolinone,":[22],"and":[23,44,54,70,73,83],"2,":[24],"its":[25],"4-":[26],"N-methylpiperidinylmethyl":[27],"analogue":[28],"(Fig.":[29],"1),":[30],"formed":[31],"the":[32,78],"basis":[33],"a":[35,92],"structure-activity":[36],"study.":[37],"The":[38],"synthesis":[39],"approximately":[41],"50":[42],"analogues":[43],"their":[45],"respective":[46],"activities":[47],"vs.":[48],"HIV":[49],"are":[50],"presented.":[51],"Both":[52],"1":[53,82],"2":[55,84],"were":[56],"effective":[57],"inhibitors":[58],"HIV(IIIb)":[60],"cell":[62,105],"protection":[63],"assays":[64],"IC90":[66],"values":[67],"4.4":[69],"14.9\u03bcM":[71],"(2.2":[72],"7.9\u03bcg":[74],"ml\u22121),":[75],"respectively.":[76],"In":[77],"same":[79],"concentration":[80],"range,":[81],"also":[85],"inhibit":[86],"syncytia":[87],"formation.":[88],"These":[89],"compounds":[90],"represent":[91],"class":[94],"agents":[97],"which":[98],"appear":[99],"to":[100],"act":[101],"by":[102],"inhibiting":[103],"virus-dependent":[104],"fusion.":[106]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}